Free press releases distribution network?

Agency / Source: Foamix Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



New U.S. Patent Grant to Foamix for its Hygroscopic and Waterless Breakable Foam Technology - The patent describes unique pharmaceutical foams and their use to deliver a wide range of active agents to treat skin and body cavity conditions (U.S Patent No. 7,704,518)
New U.S. Patent Grant to Foamix for its Hygroscopic and Waterless Breakable Foam Technology

 

PRZOOM - /newswire/ - Rehovot, Israel, 2010/05/20 - The patent describes unique pharmaceutical foams and their use to deliver a wide range of active agents to treat skin and body cavity conditions (U.S Patent No. 7,704,518).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Foamix Ltd., today announced that the United States Patent Office has granted the company a new patent on its Hygroscopic and Waterless Breakable Foam technology platform.

United States Patent No. 7,704,518, entitled “Foamable vehicle and pharmaceutical compositions thereof” claims carriers based on polyol or polyethylene glycol polar solvents, and pharmaceutical compositions and methods of treatment with a wide variety of active agents, which can be delivered to a multiplicity of sites, including skin and various body cavities, such as the vagina.

The waterless foam vehicle can be used to increase the concentration of soluble active agents, thus facilitating enhanced skin penetration of the active agent and thereby augmenting their bioavailability and dermal delivery. This technology platform can also be used for delivering drugs which are sensitive to water. In some cases, such as with non-water-sensitive ingredients, the carriers and pharmaceutical compositions may comprise up to about 10% of water.
"We are pleased to receive this new patent, which covers our unique hygroscopic and waterless foam technology platform. This patent is the eighth issued US patent in our patent estate covering our multiple technology platforms. It strengthens and expands Foamix’s intellectual property position and provides protection for innovative products in our pipeline,” said Dr. Dov Tamarkin, CEO of Foamix.

The granted claims are directed to hygroscopic and waterless foamable carriers and foams based on polyol or polyethylene glycol polar solvents, as well as pharmaceutical compositions that contain a variety of drugs, including antibacterial agents, antifungals, antiviral agents, antiparasitic agents, keratolytic agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-allergic agents, anticancer agents, local anesthetics, retinoids, photodynamic therapy agents, anti-wrinkle agents, skin whitening agents, immunosuppressants and immunomodulators.

About Foamix Ltd

Headquartered in Rehovot, Israel, Foamix (foamix.co.il) is a leading developer of topical foam and OilGel™ formulations, which can be used for dermatological, gynecological and ophthalmic applications. Foamix’s state-of-the-art foams and OilGel™ formulations provide controlled delivery of a variety of active ingredients. Foamix collaborates with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation.
To date, Foamix has twenty three issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company further has over 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Foamix Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New U.S. Patent Grant to Foamix for its Hygroscopic and Waterless Breakable Foam Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Dov Tamarkin - Foamix.co.il 
+972 8 9316233 dov[.]foamix.co.il
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Foamix Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Foamix Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com

Visit  RightITnow Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today